As part of the Company’s plans to expand its operations through new product development, the Company intends to add two new pharmaceutical plants for the production of Amoxyclav and Corticosteroid which is used in the treatment of bacterial infections. The projected capacity for the Amoxyclav and Corticosteroid plants is set at 2.85 billion tablets and 337 million tablets per annum, respectively.
Incorporated in 2005, Me Cure Industries Plc (“Me Cure”, the “Company”) is one of Nigeria’s leading healthcare providers, with an ecosystem comprising Pharmaceuticals (manufacture and distribution of pharmaceutical products) and Healthcare (medical investigations, eye care, oncology, cardiac and dental care). The Company has its factory situated in Oshodi, Lagos with distribution managed across 3 depots in Kano State, Lagos State and Anambra State.
ME CURE INDUSTRIES PLC (“ME CURE”)
Me Cure is a leading manufacturer of medicines in Nigeria. The Company has almost two decades of operational experience in medicine manufacturing in Nigeria.
The Company produces primarily branded generic and over-the-counter medicines from its pharmaceutical facility in Lagos state. The Company has 142 medicine formulations in oral solid and oral liquid form across four product segments including acute medications i.e., antibiotics, analgesics, antihistamines, antacids, and expectorants), chronic medications (i.e., antiulcer), multivitamins and nutraceuticals.
Project Highlight
As part of the Company’s plans to expand its operations through new product development, the Company intends to add two new pharmaceutical plants for the production of Amoxyclav and Corticosteroid which is used in the treatment of bacterial infections. The projected capacity for the Amoxyclav and Corticosteroid plants is set at 2.85 billion tablets and 337 million tablets per annum, respectively.
10
Billion Naira
Transaction Details
With InfraCredit’s guarantee, Me Cure secured a N10.0 billion Bank of Industry (BOI) Loan Facility
In 2024, Me Cure secured a NGN10 billion facility from the Bank of Industry (BOI), disbursed in two tranches of NGN5 billion. The proceeds of the facility financed the development of two new pharmaceutical manufacturing plants, supporting the expansion of local pharmaceutical production capacity in Nigeria.
| Issue date | 10th July 2024 | 7th October 2024 |
| Co-obligor | Me Cure Industries Plc | Me Cure Industries Plc |
| Principal Amount Outstanding | 5,000,000,000 | 5,000,000,000. |
| Sector | Social Infrastructure (Healthcare) | Social Infrastructure (Healthcare) |
| Tenor | 7 years | 7 years |
| Location of Operation | South-West, Nigeria | South-West, Nigeria |
| Asset Size & Capacity | Amoxyclav – 2.85 billion tablets P.A Coricosteroid – 337 million tablets P.A |
Amoxyclav – 2.85 billion tablets P.A Coricosteroid – 337 million tablets P.A |
Investor Distribution
Development Impact
